HSIC vs STRO
Henry Schein Inc (HSIC) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the HSIC and STRO stock pages for the full models.
Not investment advice.